3rd Consortium Meeting – Stockholm, 25–26 February 2025
The consortium gathered in Stockholm on 25–26 February 2025 to reflect on 2024’s achievements and exchange insights from the past year
INTERCEPT-T2D at the 60th EASD Congress in Madrid
INTERCEPT-T2D members convened at the 60th Annual EASD Congress in Madrid to engage with experts on inflammation and type 2 diabetes and strengthen their collaboration.
Consortium members present at the 2024 Congress of the Société Francophone du Diabète
On March 20, 2024, at the Annual Congress of the Société Francophone du Diabète, two presentations highlighted the progress of the INTERCEPT-T2D project (CHUL and AP-HP)
First patient enrolled in the project’s clinical study
First Patient Enrolled in a Phase 2 Study in Patients with Type 2 Diabetes with Olatec’s NLRP3 Inhibitor, Dapansutrile
Presentation of INTERCEPT-T2D’s Coordinator in the FFD newsletter (in french)
*Article in French* Read an article made by our partner “the Federation Française des diabétiques” about the project’s coordinator Nicolas Venteclef and the project INTERCEPT-T2D in their newsletter
2nd consortium meeting 6&7 December Basel
The consortium met again in Basel on the 6&7 of December to review the progress and accomplishments of the year 2023.
Horizon Europe – a Swiss Success Story with Prof. Dr. Marc Donath from University Hospital Basel
Listen to Dr. Marc Donath, Head of Clinic for Endocrinology, Diabetes & Metabolism, Uni Spital Basel speaking about INTERCEPT-T2D